drugset / Trial / NCT06368414

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

NCT06368414

Phase 2 Recruiting 69 enrolled Korean Society of Hematology
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI

Timeline

Start
2024-03-11
Primary completion
2028-08-31
Completion
2028-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Asciminib Unknown